Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study

Clicks: 325
ID: 5905
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #363 of 1,693 articles by views in Infection and drug resistance

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,693 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study
Reference Key
xiaoning2019entecavirinfection Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Xiaoning Wu;Jialing Zhou;Wen Xie;Huiguo Ding;Xiaojuan Ou;Guofeng Chen;Anlin Ma;Xiaoyuan Xu;Hui Ma;Youqing Xu;Xiaoqing Liu;Tongtong Meng;Lin Wang;Yameng Sun;Bingqiong Wang;Yuanyuan Kong;Hong Ma;Hong You;Jidong Jia and
Journal Infection and drug resistance
Year 2019
DOI
10.2147/IDR.S185120
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.